The use of pan-AKT inhibitor uprosertib with MEK1/2 inhibitor trametinib was also not well-tolerated, with minimal clinical advantage in continuous or intermittent dosing for patients with TNBC or BRAFWT melanoma (NCT01138085) [34]. This evidence concerns the gene MAP2K1 and melanoma.